TSBX (Turnstone Biologics) Forward Dividend Yield % : 0.00% (As of Dec. 14, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Turnstone Biologics Forward Dividend Yield %?

As of today (2024-12-14), the Forward Annual Dividend Yield of Turnstone Biologics is 0.00%.

As of today (2024-12-14), the Trailing Annual Dividend Yield of Turnstone Biologics is 0.00%.

TSBX's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.45
* Ranked among companies with meaningful Forward Dividend Yield % only.

Turnstone Biologics's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Turnstone Biologics's Forward Dividend Yield %

For the Biotechnology subindustry, Turnstone Biologics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Turnstone Biologics's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Turnstone Biologics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Turnstone Biologics's Forward Dividend Yield % falls into.

Turnstone Biologics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Turnstone Biologics (NAS:TSBX) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Turnstone Biologics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Turnstone Biologics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Turnstone Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Turnstone Biologics Corp (NAS:TSBX) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

9310 Athena Circle, Suite 300, La Jolla, CA, USA, 92037

Website

https://www.turnstonebio.com

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

Executives

Davis Jerel	director, 10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures V, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Robert J Gould	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Sammy J. Farah	director, officer: President & CEO	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Saryah Azmat	officer: Chief Business Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Venkat Ramanan	officer: Chief Financial Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Campisi Peter Joseph Jr.	officer: Chief Legal Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Vijay Chiruvolu	officer: Int. Chief Technology Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Versant Vantage Ii Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kanya Rajangam	director	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Versant Ventures V Gp-gp (canada), Inc.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Michael F. Burgess	director, officer: Interim Chief Medical Officer	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Stewart Abbot	officer: Chief Scientific Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037